Details:
Under the agreement announced today, Medis will initially focus on the commercialization of NaMuscla® in the Central and East European countries, namely Croatia, Czech Republic, Hungary, Slovakia, and Slovenia in the first phase.
Lead Product(s): Mexiletine
Therapeutic Area: Musculoskeletal Product Name: NaMuscla
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Lupin Ltd
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 09, 2022